Conestoga Capital Advisors LLC Has $33,052,000 Position in Repligen Corp. (RGEN)
Conestoga Capital Advisors LLC raised its position in shares of Repligen Corp. (NASDAQ:RGEN) by 3.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,094,805 shares of the company’s stock after buying an additional 37,217 shares during the period. Repligen Corp. makes up approximately 2.3% of Conestoga Capital Advisors LLC’s holdings, making the stock its 18th largest position. Conestoga Capital Advisors LLC owned about 3.24% of Repligen Corp. worth $33,052,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the stock. ClariVest Asset Management LLC increased its position in shares of Repligen Corp. by 15.6% in the second quarter. ClariVest Asset Management LLC now owns 37,769 shares of the company’s stock worth $1,034,000 after buying an additional 5,100 shares in the last quarter. American Century Companies Inc. increased its position in shares of Repligen Corp. by 82.6% in the second quarter. American Century Companies Inc. now owns 157,822 shares of the company’s stock worth $4,318,000 after buying an additional 71,403 shares in the last quarter. Boston Advisors LLC increased its position in shares of Repligen Corp. by 34.7% in the second quarter. Boston Advisors LLC now owns 13,755 shares of the company’s stock worth $376,000 after buying an additional 3,540 shares in the last quarter. Falcon Point Capital LLC increased its position in shares of Repligen Corp. by 12.2% in the second quarter. Falcon Point Capital LLC now owns 35,023 shares of the company’s stock worth $958,000 after buying an additional 3,815 shares in the last quarter. Finally, Strs Ohio increased its position in shares of Repligen Corp. by 9.6% in the second quarter. Strs Ohio now owns 35,400 shares of the company’s stock worth $968,000 after buying an additional 3,100 shares in the last quarter. Institutional investors own 95.82% of the company’s stock.
Shares of Repligen Corp. (NASDAQ:RGEN) traded down 1.40% during trading on Monday, hitting $32.50. The company had a trading volume of 474,664 shares. The stock’s 50-day moving average price is $29.93 and its 200 day moving average price is $28.50. Repligen Corp. has a 52 week low of $20.07 and a 52 week high of $33.79. The company has a market capitalization of $1.10 billion, a P/E ratio of 157.00 and a beta of 1.63.
Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Thursday, November 3rd. The company reported $0.08 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.08. The firm earned $24.70 million during the quarter, compared to analysts’ expectations of $24.39 million. Repligen Corp. had a return on equity of 10.16% and a net margin of 6.89%. The company’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 EPS. On average, equities research analysts forecast that Repligen Corp. will post $0.45 earnings per share for the current year.
Separately, Zacks Investment Research upgraded Repligen Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 11th.
In other news, Director Thomas F. Ryan, Jr. sold 2,700 shares of Repligen Corp. stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $32.58, for a total value of $87,966.00. Following the completion of the transaction, the director now owns 9,394 shares in the company, valued at approximately $306,056.52. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.30% of the stock is owned by insiders.
Repligen Corp. Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Receive News & Stock Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related stocks with our FREE daily email newsletter.